Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Lymphoid 3Gastrointestinal 3Plasma cell 2NET 2Endocrine 2Breast 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Positron Emission Tomography Computed Tomography × Plasma cell × Clear all
NCT03314636 2025-08-08

CONPET

Oslo University Hospital

Phase 2 Active not recruiting
53 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT04467281 2022-07-01

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡